Dana Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.5M Sell
36,422
-4,611
-11% -$4.67M 1% 14
2025
Q4
$44.1M Sell
41,033
-2,481
-6% -$2.37M 1.28% 10
2025
Q3
$33.2M Buy
43,514
+7,542
+21% +$5.61M 0.97% 15
2025
Q2
$28M Buy
35,972
+1,211
+3% +$941K 0.93% 17
2025
Q1
$28.7M Buy
34,761
+478
+1% +$398K 1.03% 15
2024
Q4
$26.5M Buy
34,283
+12,919
+60% +$10.7M 0.87% 18
2024
Q3
$18.9M Buy
21,364
+728
+4% +$655K 0.63% 37
2024
Q2
$18.7M Sell
20,636
-289
-1% -$231K 0.63% 32
2024
Q1
$16.3M Buy
20,925
+800
+4% +$569K 0.54% 41
2023
Q4
$11.7M Buy
20,125
+16,106
+401% +$9.4M 0.57% 54
2023
Q3
$2.16M Sell
4,019
-454
-10% -$234K 0.11% 139
2023
Q2
$2.1M Buy
4,473
+962
+27% +$403K 0.1% 135
2023
Q1
$1.21M Sell
3,511
-418
-11% -$141K 0.06% 211
2022
Q4
$1.44M Buy
3,929
+106
+3% +$37.6K 0.08% 184
2022
Q3
$1.24M Buy
3,823
+2,280
+148% +$722K 0.07% 185
2022
Q2
$500K Buy
+1,543
New +$463K 0.03% 307

Other funds holding LLY

Dana Investment Advisors's LLY Position: Q1 2026 in Review

Dana Investment Advisors reduced its Eli Lilly (LLY) stake by 11% in Q1 2026, selling an estimated $4.67M and leaving 36,422 shares worth $33.5M. The position accounts for 1% of the portfolio, ranked #14.

Dana Investment Advisors first reported a position in LLY in Q2 2022 and has held it in 16 quarters since. The position peaked at $44.1M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Dana Investment Advisors held 36,422 shares of Eli Lilly worth $33.5M as of Q1 2026.
  • Dana Investment Advisors sold 4,611 Eli Lilly shares in Q1 2026, an estimated $4.67M.
  • Eli Lilly made up 1% of Dana Investment Advisors's portfolio in Q1 2026, its #14 holding.
  • Dana Investment Advisors first reported a position in Eli Lilly in Q2 2022 and has held it in 16 quarters since.
  • Dana Investment Advisors's Eli Lilly position peaked at $44.1M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Dana Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.